Specialist medical supplier Durbin has appointed Todd Galles as its business development principal in the US in a permanent capacity.
Galles first joined the UK-headquartered firm in 2014, serving as its US representative in a part-time role, and will now be responsible for growing its clinical trial supply and managed access business there.
He brings over 30 years of sales, marketing and business development experience in the pharma and biotech industries, and has held a number of executive management roles during this time.
Prior to joining Durbin, Galles served as director of business development at C3 Research Associates, business development US liaison for Japanese contract research organisation CMIC, and business development director at US firm BDC.
He also brings experience from dermatology CRO bioskin, medical device and biotech CRO Boston Biomedical Associates, and clinical and data management firm ProPharma Group.
Robert Donnell, head of business development at Durbin, said: “Todd has supported business development outreach in the US part-time for Durbin for more than two years, so now we’re delighted to have him on-board full-time.
“Todd brings a huge amount of experience and enthusiasm to the role, and I look forward to continuing to work with him to develop and grow our US business.”